Onena Medicines Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 15

Onena Medicines General Information

Description

Developer of an antibody drug discovery platform designed to reprogram cancer cells to treat advanced cancers, centered around proprietary artificial intelligence. The company's platform designs custom antibodies with high selectivity and specificity linked to proprietary cellular reprogramming lab assays, its drugs modulate activities of a novel set of growth factors called dual smad inhibiting protein dips, thought to drive the growth and spread of cancer, enabling physicians to get access to novel drugs in areas of unmet medical needs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Hegenheimermattweg 167A
  • Switzerland Innovation Park Basel Area
  • 4123 Allschwil
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Hegenheimermattweg 167A
  • Switzerland Innovation Park Basel Area
  • 4123 Allschwil
  • Switzerland

Onena Medicines Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Onena Medicines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC 26-Mar-2025 Completed Pre-Clinical Trials
12. Early Stage VC 04-Dec-2023 Cancelled Pre-Clinical Trials
11. Early Stage VC 31-Oct-2023 Completed Pre-Clinical Trials
10. Grant 31-Oct-2023 Completed Pre-Clinical Trials
9. Accelerator/Incubator 27-May-2022 Completed Pre-Clinical Trials
8. Accelerator/Incubator 11-May-2022 Completed Pre-Clinical Trials
7. Accelerator/Incubator 01-Apr-2022 Completed Product In Beta Test
6. Early Stage VC 01-Oct-2021 Completed Product In Beta Test
5. Accelerator/Incubator 02-Jun-2020 $273K Completed Product In Beta Test
4. Early Stage VC 01-Jun-2020 $273K $273K Completed Product In Beta Test
To view Onena Medicines’s complete valuation and funding history, request access »

Onena Medicines Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Onena Medicines’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Onena Medicines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an antibody drug discovery platform designed to reprogram cancer cells to treat advanced cancers, centered
Drug Discovery
Allschwil, Switzerland
9 As of 2026

Boston, MA
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Onena Medicines Competitors (8)

One of Onena Medicines’s 8 competitors is Incendia Therapeutics, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Incendia Therapeutics Venture Capital-Backed Boston, MA
FoRx Therapeutics Venture Capital-Backed Basel, Switzerland
HiberCell Venture Capital-Backed Roseville, MN
Absci Formerly VC-backed Vancouver, WA
Inhibitec Accelerator/Incubator Backed Santander, Spain
You’re viewing 5 of 8 competitors. Get the full list »

Onena Medicines Patents

Onena Medicines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4182475-A2 Antibodies against lefty proteins Pending 17-Jul-2020
US-20240368259-A1 Antibodies against lefty proteins Pending 17-Jul-2020
WO-2022013613-A2 Antibodies against lefty proteins Inactive 17-Jul-2020
WO-2022013613-A3 Antibodies against lefty proteins Inactive 17-Jul-2020
WO-2022013613-A8 Antibodies against lefty proteins Inactive 17-Jul-2020 C07K16/22
To view Onena Medicines’s complete patent history, request access »

Onena Medicines Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Onena Medicines Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Olive Venture Partners Venture Capital Minority
Plug and Play Accelerator/Incubator Minority
Avanteca Partners Other Minority
Bic Gipuzkoa Accelerator/Incubator
EUREKA Network Accelerator/Incubator
You’re viewing 5 of 15 investors. Get the full list »

Onena Medicines FAQs

  • When was Onena Medicines founded?

    Onena Medicines was founded in 2019.

  • Where is Onena Medicines headquartered?

    Onena Medicines is headquartered in Allschwil, Switzerland.

  • What is the size of Onena Medicines?

    Onena Medicines has 9 total employees.

  • What industry is Onena Medicines in?

    Onena Medicines’s primary industry is Drug Discovery.

  • Is Onena Medicines a private or public company?

    Onena Medicines is a Private company.

  • What is Onena Medicines’s current revenue?

    The current revenue for Onena Medicines is .

  • How much funding has Onena Medicines raised over time?

    Onena Medicines has raised $2.47M.

  • Who are Onena Medicines’s investors?

    Olive Venture Partners, Plug and Play, Avanteca Partners, Bic Gipuzkoa, and EUREKA Network are 5 of 15 investors who have invested in Onena Medicines.

  • Who are Onena Medicines’s competitors?

    Incendia Therapeutics, FoRx Therapeutics, HiberCell, Absci, and Inhibitec are some of the 8 competitors of Onena Medicines.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process